Michael C Roach1, Sana Rehman1, Todd A DeWees1, Christopher D Abraham1, Jeffrey D Bradley1, Cliff G Robinson2. 1. Department of Radiation Oncology, Siteman Cancer Center, Washington University in Saint Louis, St. Louis, Missouri. 2. Department of Radiation Oncology, Siteman Cancer Center, Washington University in Saint Louis, St. Louis, Missouri. Electronic address: crobinson@radonc.wustl.edu.
Abstract
PURPOSE: As stereotactic body radiation therapy (SBRT) has emerged as a quick, effective, and well-tolerated treatment for early stage non-small cell lung carcinoma (NSCLC), it can be difficult to convince patients to quit smoking in follow-up. We evaluated whether there was a survival benefit to smoking cessation after SBRT. METHODS AND MATERIALS: Patients with early-stage NSCLC treated from 2004 to 2013 who were still smoking tobacco at the time of SBRT were identified from a prospective institutional review board-approved registry. Peripheral tumors were treated to 54 Gy in 3 fractions and central tumors to 50 Gy in 5 fractions. Patients were reviewed for overall survival (OS) and disease progression. The log-rank and Cox regression tests were used to identify factors predictive of OS. RESULTS: Thirty-two patients (27%) quit smoking after SBRT, and 87 (73%) continued smoking. Median follow-up was 22 months (range, 2-87). On multivariate analysis, smoking status (hazard ratio, 2.1; 95% confidence interval, 1.02-4.2; P = .045), increasing age-adjusted Charlson comorbidity score and larger tumor size were predictive of worse OS. The prior number of cigarette pack-years was not significant (P = .62). In a Kaplan-Meier comparison, smoking cessation after SBRT was associated with improved 2-year OS, 78% versus 69% (P = .014). There was no significant difference in 2-year progression-free survival (75% vs 55%, P = .23) or local control (97% vs 88%, P = .63). CONCLUSION: OS is significantly improved in patients who stop smoking after SBRT for early-stage NSCLC, no matter their previous smoking history. Encouraging smoking cessation should be an important part of every posttreatment visit.
PURPOSE: As stereotactic body radiation therapy (SBRT) has emerged as a quick, effective, and well-tolerated treatment for early stage non-small cell lung carcinoma (NSCLC), it can be difficult to convince patients to quit smoking in follow-up. We evaluated whether there was a survival benefit to smoking cessation after SBRT. METHODS AND MATERIALS: Patients with early-stage NSCLC treated from 2004 to 2013 who were still smoking tobacco at the time of SBRT were identified from a prospective institutional review board-approved registry. Peripheral tumors were treated to 54 Gy in 3 fractions and central tumors to 50 Gy in 5 fractions. Patients were reviewed for overall survival (OS) and disease progression. The log-rank and Cox regression tests were used to identify factors predictive of OS. RESULTS: Thirty-two patients (27%) quit smoking after SBRT, and 87 (73%) continued smoking. Median follow-up was 22 months (range, 2-87). On multivariate analysis, smoking status (hazard ratio, 2.1; 95% confidence interval, 1.02-4.2; P = .045), increasing age-adjusted Charlson comorbidity score and larger tumor size were predictive of worse OS. The prior number of cigarette pack-years was not significant (P = .62). In a Kaplan-Meier comparison, smoking cessation after SBRT was associated with improved 2-year OS, 78% versus 69% (P = .014). There was no significant difference in 2-year progression-free survival (75% vs 55%, P = .23) or local control (97% vs 88%, P = .63). CONCLUSION:OS is significantly improved in patients who stop smoking after SBRT for early-stage NSCLC, no matter their previous smoking history. Encouraging smoking cessation should be an important part of every posttreatment visit.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Joseph W Ditre; Brian D Gonzalez; Vani N Simmons; Leigh Anne Faul; Thomas H Brandon; Paul B Jacobsen Journal: Pain Date: 2011-01 Impact factor: 6.961
Authors: Kevin L Stephans; Toufik Djemil; Rahul D Tendulkar; Cliff G Robinson; Chandana A Reddy; Gregory M M Videtic Journal: Int J Radiat Oncol Biol Phys Date: 2011-02-06 Impact factor: 7.038
Authors: Cliff G Robinson; Todd A DeWees; Issam M El Naqa; Kimberly M Creach; Jeffrey R Olsen; Traves D Crabtree; Bryan F Meyers; Varun Puri; Jennifer M Bell; Parag J Parikh; Jeffrey D Bradley Journal: J Thorac Oncol Date: 2013-02 Impact factor: 15.609
Authors: Kathryn E Weaver; Suzanne C Danhauer; Janet A Tooze; A William Blackstock; John Spangler; Leslie Thomas; Erin L Sutfin Journal: Oncologist Date: 2012-02-14
Authors: Andrew N Hughes; Mary E R O'Brien; W Jeffrey Petty; Jonathan B Chick; Elaine Rankin; Penella J Woll; David Dunlop; Marianne Nicolson; Ramesh Boinpally; Julie Wolf; Allan Price Journal: J Clin Oncol Date: 2009-01-21 Impact factor: 44.544
Authors: Allison J Carroll; Anna K Veluz-Wilkins; Sonja Blazekovic; Ravi Kalhan; Frank T Leone; E Paul Wileyto; Robert A Schnoll; Brian Hitsman Journal: Psychooncology Date: 2017-08-04 Impact factor: 3.894
Authors: M Shayne Gallaway; Rebecca Glover-Kudon; Behnoosh Momin; Mary Puckett; Natasha Buchanan Lunsford; Kathleen R Ragan; Elizabeth A Rohan; Stephen Babb Journal: J Cancer Surviv Date: 2019-01-05 Impact factor: 4.442
Authors: Ramzi G Salloum; Heather D'Angelo; Ryan P Theis; Betsy Rolland; Sarah Hohl; Danielle Pauk; Jennifer H LeLaurin; Yasmin Asvat; Li-Shiun Chen; Andrew T Day; Adam O Goldstein; Brian Hitsman; Deborah Hudson; Andrea C King; Cho Y Lam; Katie Lenhoff; Arnold H Levinson; Judith Prochaska; Fabrice Smieliauskas; Kathryn Taylor; Janet Thomas; Hilary Tindle; Elisa Tong; Justin S White; W Bruce Vogel; Graham W Warren; Michael Fiore Journal: Implement Sci Commun Date: 2021-04-09
Authors: Annika Ryan; Alison Luk Young; Jordan Tait; Kristen McCarter; Melissa McEnallay; Fiona Day; James McLennan; Catherine Segan; Gillian Blanchard; Laura Healey; Sandra Avery; Sarah White; Shalini Vinod; Linda Bradford; Christine L Paul Journal: Health Serv Outcomes Res Methodol Date: 2022-09-28
Authors: Elizabeth A Rohan; Nina Miller; Floyd Bonner; Kristi Fultz-Butts; Mandi L Pratt-Chapman; Catherine M Alfano; Kristen Cox Santiago; Kendall Bergman; Eric Tai Journal: Cancer Causes Control Date: 2018-12-01 Impact factor: 2.506